FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “ Impel NeuroPharma, Inc Granted U.S. FDA Approval for its Acute Migraine Treatment”
Impel NeuroPharma, Inc. (NASDAQ: IMPL) surged over 46% in premarket trading after the company announced that the U.S. FDA approved the TRUDHESA™ nasal spray for the acute treatment of migraine with or without aura in adults.
Previously known as INP104, TRUDHESA is the first and only therapeutic to use POD technology to deliver dihydroergotamine mesylate to the vascular-rich upper nasal space, offering rapid, sustained, and consistent symptom relief without injection or infusion.
Impel NeuroPharma, Inc. is a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. Impel offers and is developing treatments that pair its proprietary Precision Olfactory Delivery (POD®) technology with well-established therapeutics. In addition to TRUDHESA™ (dihydroergotamine mesylate) nasal spray, which is approved in the United States for the acute treatment of migraine with or without aura in adults, impel is also developing INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.
For more information, please visit: Impel NeuroPharma, Inc.
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.